Optimizing Decision-Making in CLL in an Era of Novel Agents

Download All
A comprehensive educational program featuring expert insight commentaries, an Interactive Treatment Decision Support tool, and a series of microeducation modules to fortify your practice in managing patients with CLL.
Anthony Mato, MD, MSCE
William G. Wierda, MD, PhD

ClinicalThought

With the recent approval of ibrutinib plus rituximab for the frontline treatment of CLL, how should therapeutic choices be made in an increasingly complex landscape? Here’s my approach.

Anthony Mato, MD, MSCE Released: June 26, 2020

In this commentary, experts share their thoughts on key phase III trials of BTK inhibitors in CLL that were recently presented at ASCO 2021 and EHA 2021.

Anthony Mato, MD, MSCE William G. Wierda, MD, PhD Released: July 28, 2021
Provided by University of South Florida (USF) Health in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
CLL Society Logo
Educational grant provided by:
AbbVie Inc.
AstraZeneca
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings